Key Highlights: Implications: Viatris is selling up to 92 million Biocon shares (about 5.6% of the company) in a secondary sale, so Biocon gets no money from it; the deal is priced at a di...
Key Highlights: Implications: This is a strategic diversification move: Anupam Rasayan is using Bliss GVS to enter pharmaceutical formulations and move further up the healthcare value chai...
